Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry
Inflammatory Bowel Diseases · 01.08.2026 · 32 (8) · 1460-1470
DOI: 10.1093/ibd/izag045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.04.2026. Verfasst von Loriane M M Verleye und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Maastricht UMC+, 6229 HX Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch ICC.
Abstract (Originalsprache)
Background
Risankizumab, a monoclonal antibody targeting interleukin-23, is approved for the treatment of Crohn’s disease (CD). Real-world evidence on its effectiveness remains limited. We assessed 1-year effectiveness and safety of risankizumab in a prospective cohort of patients with CD, emphasizing difficult-to-treat disease.
Methods
Data were retrieved from the Dutch Initiative on Crohn and Colitis Registry. At baseline and at weeks 12, 24, and 52, clinical remission (Harvey-Bradshaw Index ≤4), biochemical remission (fecal calprotectin ≤250 µg/g and C-reactive protein levels ≤5 mg/L), systemic corticosteroids use, and safety outcomes were determined. The primary outcome was corticosteroid-free clinical remission (CSFCR) at week 24. Difficult-to-treat disease was defined as the failure of advanced therapies with at least 2 different mechanisms of action.
Results
In total, 151 patients initiated risankizumab before August 1, 2025; 136 (90.1%) of 151 patients had difficult-to-treat disease. At baseline, 90 (59.6%) patients had Harvey-Bradshaw Index >4. Of those, at week 24, 31 (50%) of 62 patients were in CSFCR; this rate was 53.3% when including all patients. Analysis including only patients with difficult-to-treat disease revealed that 51.8% of these patients were in CSFCR at week 24. Twenty-two (14.6%) patients discontinued treatment after a median of 183.5 days (Q1-Q3: 90.0-295.2 days), most following nonresponse. Regarding adverse events, 35.3 possibly and 16.6 probably risankizumab-related events per 100 person-years were reported.
Conclusion
In this prospective multicenter study, risankizumab demonstrated favorable effectiveness and safety profile in patients with CD, including those with difficult-to-treat disease, bowel surgery, and stoma. These findings support the use of risankizumab in patients with difficult-to-treat disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Maastricht UMC+, 6229 HX Maastricht, the Netherlands.
- NUTRIM Institute for Nutrition and Translational Research in Metabolism, Maastricht University, 6229 ER Maastricht, the Netherlands.
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center, 3015 GD Rotterdam, the Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
- Department of Gastroenterology and Hepatology, Radboudumc, 6525 GA Nijmegen, the Netherlands.
ORCID-Profile: Loriane M M Verleye, Annemarie C de Vries, Fiona D M van Schaik, Andrea E van der Meulen-de Jong, Willemijn A van Dop, Mark Löwenberg, Marijn C Visschedijk, Myrthe R Naber, Dianne G Bouwknegt, Tessa E H Römkens, Alexander G L Bodelier, Philip W Voorneveld, Bas Oldenburg, Lauranne A A P Derikx, Marjolijn Duijvestein, Zlatan Mujagić
Förderung
- Dutch ICC
Zitieren
APA
Verleye, L. M. M., Pierik, M. J., de Vries, A. C., van Schaik, F. D. M., van der Meulen-de Jong, A. E., van Dop, W. A., Löwenberg, M., Visschedijk, M. C., Naber, M. R., Bouwknegt, D. G., Römkens, T. E. H., Bodelier, A. G. L., Voorneveld, P. W., Oldenburg, B., Derikx, L. A. A. P., Duijvestein, M., Mujagić, Z., & Dutch Initiative on Crohn and Colitis (ICC) (2026). Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry. Inflammatory Bowel Diseases, 32(8), 1460-1470. https://doi.org/10.1093/ibd/izag045
Vancouver
Verleye LMM, Pierik MJ, de Vries AC, van Schaik FDM, van der Meulen-de Jong AE, van Dop WA, et al. Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry. Inflammatory Bowel Diseases. 2026;32(8):1460-1470. doi:10.1093/ibd/izag045
BibTeX
@article{Verleye2026,
author = {Verleye, Loriane M M and Pierik, Marieke J and de Vries, Annemarie C and van Schaik, Fiona D M and van der Meulen-de Jong, Andrea E and van Dop, Willemijn A and Löwenberg, Mark and Visschedijk, Marijn C and Naber, Myrthe R and Bouwknegt, Dianne G and Römkens, Tessa E H and Bodelier, Alexander G L and Voorneveld, Philip W and Oldenburg, Bas and Derikx, Lauranne A A P and Duijvestein, Marjolijn and Mujagić, Zlatan and Dutch Initiative on Crohn and Colitis (ICC), Dutch Initiative on Crohn and Colitis (ICC)},
title = {Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {8},
pages = {1460--1470},
doi = {10.1093/ibd/izag045}
}
EUVIMED